Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Quadruplets, Bispecific Antibodies, and CAR T-Cell Therapies Usher in Advances in Multiple Myeloma

May 27th 2022

Noopur Raje, MD, reviews the benefits of quadruplet regimens in the up-front and relapsed settings, treatment options for relapsed/refractory disease, and the possibilities for combinations to minimize toxicities in those who receive CAR T-cell or bispecific antibody therapies.

Triple-Class Refractory MM: Factors in Selecting Optimal Therapy

May 26th 2022

Shared insight on factors that help to determine optimal therapy for patients diagnosed with triple-class refractory multiple myeloma.

Patient Scenario 1: A 66-Year-Old With Triple-Class Refractory MM

May 26th 2022

Expert hematologist-oncologist Adriana Rossi, MD, shares a real-world patient scenario of triple-class refractory multiple myeloma managed with novel bispecific antibody therapy.

Selinexor Combo Approaches EU Approval for Refractory Multiple Myeloma

May 20th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of selinexor in combination with bortezomib and low-dose dexamethasone for use in adult patients with multiple myeloma who have previously received 1 to 3 prior lines of treatment.

Trial Assessing CAR T-Cell Therapy ACLX-001 in Relapsed/Refractory Multiple Myeloma Begins

May 19th 2022

Investigators have initiated a phase 1 trial exploring ACLX-001, a novel CAR T-cell therapy using the ARC-SparX platform, in patients with relapsed/refractory multiple myeloma.

Isatuximab Combo Significantly Improves PFS in Relapsed Multiple Myeloma

May 16th 2022

The addition of isatuximab-irfc to carfilzomib and dexamethasone resulted in a significant improvement in progression-free survival vs carfilzomib plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Teclistamab/Daratumumab Combo Delivers Promising ORR in Heavily Pretreated Relapsed/Refractory Myeloma

May 10th 2022

Paula Rodriguez-Otero, MD, PhD, discusses the rationale, design, and findings of the phase 1b TRIMM-2 trial assessing subcutaneous teclistamab in combination with daratumumab for the treatment of patients with relapsed/refractory multiple myeloma.

FDA-Approved CAR T-Cell Therapies Illuminate Advances in Multiple Myeloma

May 9th 2022

Noopur S. Raje, MD, discussed the presentation she gave at the 26th Annual International Congress on Hematologic Malignancies® on the CAR T-cell therapy product bb21217, other exciting myeloma treatments that were presented at ASH, and the need for increased treatment accessibility.

Cilta-Cel Induces Impressive ORR in Relapsed/Refractory Multiple Myeloma

May 3rd 2022

Thomas Martin, MD, discusses updates from the CARTITUDE-1 trial, as well as the future of CARs and bispecific T cell engagers in multiple myeloma.

Four Baseline Characteristics Predict CR/sCR in Multiple Myeloma

April 25th 2022

Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.

Single Infusion of Cilta-Cel Elicits Early Responses in Myeloma

April 25th 2022

Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.

Dr. Lin on Treatment Updates in CAR T-Cell Therapy in Myeloma

April 21st 2022

Yi Lin, MD, PhD, discusses treatment updates in CAR T-cell therapy in multiple myeloma.

Dr. Larocca on Recent Advancements in R/R Multiple Myeloma

April 6th 2022

Alessandra Larocca, MD, PhD, discusses recent advancements in relapsed/refractory multiple myeloma.

Precursor Conditions Unlock Potential for Early Interventions in Multiple Myeloma

March 29th 2022

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.

BCMA-Targeting Therapies for RRMM: Future Perspectives

March 28th 2022

Considerations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.

Sequencing BCMA-Targeted Therapies in RRMM

March 28th 2022

Current combination approaches, including BCMA-targeting agents like belantamab mafodotin, being explored to address treatment gaps in relapsed/refractory multiple myeloma.

BCMA-Targeting Bispecifics for the Treatment of RRMM

March 28th 2022

An overview of novel bispecific therapies under development in relapsed/refractory multiple myeloma.

Fixed-Duration Therapy Struggles to Find Footing Across Tumor Types

March 28th 2022

Fixed-duration systemic therapies have gained some traction in hematologic malignancies, where advances in drug development and sequencing strategies have afforded investigators the opportunity to conduct trials.

Geriatric Assessment May Aid Treatment Decisions for Difficult-to-Treat Multiple Myeloma

March 24th 2022

Alessandra Larocca, MD, PhD, discusses the use of patient- and disease-related factors that affect treatment decisions for elderly and frail patients with relapsed/refractory multiple myeloma.

Embracing the Challenge and the Grind: Paul G. Richardson is a Giant of Cancer Care in Myeloma

March 23rd 2022

Paul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.